Submitted on August 26, 2008
Revised on November 17, 2008
Accepted on November 18, 2008
Urinary fatty acid binding protein 1: An early predictive biomarker of kidney injury
Eisei NOIRI1*, Kent Doi2, Kousuke Negishi, Tamami Tanaka, Yoshifumi Hamasaki3, Toshiro Fujita4, Didier Portilla5, and Takeshi Sugaya6
1 The Univ. of TOKYO
2 NIH
3 The Univ. of Tokyo
4 University of Tokyo School of Medicine
5 Univ. of Arkansas for Medical Sciences
6 RIKEN
* To whom correspondence should be addressed. E-mail: noiri-tky{at}umin.ac.jp.
For the development of novel therapeutic strategy of kidney disease, new renal biomarkers for early detection and accurate evaluation of renal injury is urgently required both in acute kidney injury (AKI) and chronic kidney disease (CKD). Fatty acid binding protein 1 (FABP1) is expressed in renal proximal tubular cells and shed into urine in response to hypoxia caused by decreased peritubular capillary blood flow. To clarify the role of urinary FABP1 in kidney disease, we established human FABP1 transgenic mice and evaluated the responses of FABP1 to several AKI and CKD models. Moreover, there are accumulating clinical data that urinary FABP1 can detect human AKI earlier than serum creatinine and distinguish risk population for AKI. Investigation with "humanized" FABP1 transgenic mice and measurement of clinical samples allowed us to develop urinary FABP1 as a new renal biomarker. Further clinical studies are necessary to confirm the potential of urinary FABP1 for clinical application.
